triazoles has been researched along with azacitidine in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (4.35) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (13.04) | 29.6817 |
2010's | 14 (60.87) | 24.3611 |
2020's | 5 (21.74) | 2.80 |
Authors | Studies |
---|---|
Levi, JA; Wiernik, PH | 1 |
Kikuchi, K; Kobayashi, H; Kuriyama, K; Mori, Y; Togashi, T; Tokuji, Y; Yamamoto, N | 1 |
Steensma, DP; Tefferi, A | 1 |
Ozawa, K | 1 |
Albasanz, JL; Barrachina, M; Buira, SP; Dentesano, G; Ferrer, I; Martín, M; Moreno, J | 1 |
Tefferi, A | 1 |
Miyazaki, Y | 1 |
Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
Allen, PB; Baer, MR; Kleinberg, ME; Koka, R | 1 |
Kami, M; Kobayashi, K; Nishikawa, Y; Okuda, S; Takebayashi, C; Tanimoto, T | 1 |
Guinea de Castro, JM; Moreno de Gusmão, B; Oiartzabal, I; Perez-Persona, E | 1 |
Alkhaeir, S; Callens, C; Damaj, G; Dussiot, M; Gorin, NC; Hermine, O; Isnard, F; Marolleau, JP; Monteiro, RC; Moura, IC; Paubelle, E; Rubio, MT; Suarez, F; Zylbersztejn, F | 1 |
Tohyama, K | 1 |
Bhatnagar, B; Blum, W; Devine, S; Garzon, R; Hofstetter, J; Kauffman, M; Klisovic, R; Marcucci, G; Phelps, MA; Ranganathan, P; Santhanam, R; Shacham, S; Vasu, S; Walker, A; Walsh, K; Yu, X | 1 |
Imanishi, S; Ohsuga, M; Ohyashiki, JH; Ohyashiki, K; Takahashi, R | 1 |
Arnan, M; Duarte, RF; Pomares, H; Sánchez-Ortega, I; Sureda, A | 1 |
Chen, Q; Gu, J; Li, N; Li, S; Wang, W; Wang, X; Wang, Z; Zhao, G | 1 |
Estey, EH; Percival, MM | 1 |
Ertl, IE; Hassler, MR; Ilijazi, D; Lemberger, U; Shariat, SF | 1 |
Pilko, A; Wollman, R; Zhang, T | 1 |
Chen, TT; Cheng, FM; Lin, CC; Tien, JZ; Yeh, SP | 1 |
Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J | 1 |
Ding, K; Duan, L; Fu, R; Guo, Y; Liu, Z; Shen, H | 1 |
6 review(s) available for triazoles and azacitidine
Article | Year |
---|---|
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
[Pathophysiology, diagnosis and treatment of anemia].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles | 2008 |
[MDS].
Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles | 2012 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
Epigenetic alterations of testicular germ cell tumours.
Topics: Antineoplastic Agents; Azacitidine; Azepines; Biomarkers, Tumor; Cinnamates; DNA Methylation; Epigenesis, Genetic; Humans; Imidazoles; Male; MicroRNAs; Neoplasms, Germ Cell and Embryonal; RNA, Untranslated; Testicular Neoplasms; Triazoles | 2020 |
2 trial(s) available for triazoles and azacitidine
Article | Year |
---|---|
A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Azacitidine; Digestive System; Female; Fever; Guanazole; Humans; Infusions, Parenteral; Leukemia; Leukopenia; Male; Middle Aged; Remission, Spontaneous; Time Factors; Triazoles | 1976 |
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Patient Safety; Prognosis; Survival Rate; Triazoles | 2020 |
15 other study(ies) available for triazoles and azacitidine
Article | Year |
---|---|
Formation of embryogenic cell clumps from carrot epidermal cells is suppressed by 5-azacytidine, a DNA methylation inhibitor.
Topics: 2,4-Dichlorophenoxyacetic Acid; Azacitidine; Cell Differentiation; Daucus carota; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Developmental; Gene Expression Regulation, Plant; Plant Epidermis; Triazoles | 2005 |
DNA methylation regulates adenosine A(2A) receptor cell surface expression levels.
Topics: Azacitidine; Cell Line; Chromatin Immunoprecipitation; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation; HeLa Cells; Humans; Immunoprecipitation; Methyl-CpG-Binding Protein 2; Neuroblastoma; Protein Binding; Radioligand Assay; Receptor, Adenosine A2A; Receptors, Cell Surface; RNA, Messenger; S-Adenosylmethionine; Time Factors; Triazines; Triazoles; Tritium | 2010 |
Myelodysplastic syndromes--many new drugs, little therapeutic progress.
Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles | 2010 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Scedosporium apiospermum soft tissue infection as the initial presentation of acute myeloid leukemia: a case report.
Topics: Aged, 80 and over; Amputation, Surgical; Antifungal Agents; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Humans; Leg Ulcer; Leukemia, Myeloid, Acute; Mycoses; Pancytopenia; Pyrimidines; Scedosporium; Soft Tissue Infections; Triazoles; Voriconazole | 2013 |
A case of late onset erythropoietic protoporphyria associated with myelodysplastic syndrome treated by the combination of beta carotene and azacitidine.
Topics: Aged; Azacitidine; Benzoates; beta Carotene; Deferasirox; Humans; Male; Myelodysplastic Syndromes; Protoporphyria, Erythropoietic; Triazoles | 2013 |
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles | 2014 |
Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Case-Control Studies; Cell Differentiation; Deferasirox; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cells; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Triazoles; Vitamin D | 2013 |
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA Modification Methylases; Exportin 1 Protein; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Cells, Cultured; Up-Regulation | 2015 |
Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Deferasirox; HL-60 Cells; Humans; Iron Chelating Agents; Leukemia; Triazoles; U937 Cells | 2015 |
Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Topics: Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antifungal Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic-Myeloproliferative Diseases; Neutropenia; Numbers Needed To Treat; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed; Triazoles | 2016 |
Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzoates; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Decitabine; Deferasirox; Drug Synergism; Gene Expression Regulation; Humans; Iron Chelating Agents; Leukemia; Reactive Oxygen Species; Triazoles | 2017 |
Loci specific epigenetic drug sensitivity.
Topics: Acetylation; Azacitidine; Azepines; Chromosomes, Human; DNA Methylation; Epigenesis, Genetic; Genes, Reporter; Genetic Loci; Genomics; Histones; Humans; K562 Cells; Sequence Analysis, DNA; Triazoles | 2020 |
Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Creatinine; Cytochrome P-450 Enzyme Inhibitors; Drug Administration Schedule; Drug Synergism; Female; Humans; Hyperuricemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Sulfonamides; Triazoles; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Young Adult | 2020 |
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
Topics: Azacitidine; Humans; Hydrazines; Myelodysplastic Syndromes; Neoplasms; Triazoles; Tumor Suppressor Protein p53 | 2022 |